Skip to main content

Bradley Canino

Analyst

Guggenheim

Equibles does not estimate personal net worth.

About Bradley Canino

Bradley Canino is recorded as Analyst at Guggenheim. Bradley Canino has spoken on 2 earnings calls and 1 other investor event across 3 companies, most recently for Bicara Therapeutics Inc. on August 11, 2026. Those appearances were for Bicara Therapeutics Inc. (BCAX), Celcuity Inc. (CELC) and Relay Therapeutics, Inc. (RLAY). The companies whose calls Bradley Canino spoke on are classified in the Healthcare sector.

Bradley Canino on recent calls

“Well, it's definitely rare you get to congratulate so many people at once, so it's great to see the continuity for the company as well. Two check-in questions for me.”
Analyst — Guggenheim, Bicara Therapeutics Inc. Q2 FY2026 Earnings Call ·
“Now that we have the data, maybe some commercial questions. I guess with this profile, what do you think GEDIC can achieve in the PIC3C and Mutant subgroup? Annualized cappy sales look to be about $700 million in the U.S. geography, if I've got that right.”
Analyst — Guggenheim, Phase 3 VIKTORIA-1 PIK3CA Mutant Cohort Clinical Trial Results Conference Call ·
“Can we just double-click on the prior question with some more details about how you believe whether you are or are leaving efficacy on the table by not bringing forward the 400-MIG BID oncology dose?”
Analyst — Guggenheim, Relay Therapeutics Conference Call: Initial Clinical Data for Zovegalisib in Vascular Anomalies ·

Affiliation history

  • Guggenheim

    Analyst

    Transcript header (unverified)

    Current

Company network

Recent activity